Pfizer shares swollen by danuglipron data in weight loss

24 May 2023

US pharma giant Pfizer (NYSE: PFE) was trading nearly 8% higher on Tuesday than it was at the end of last week.

A major reason for this was the publication in JAMA of Phase II results on the impact on weight loss of the oral small molecule glucagon-like peptide 1 receptor agonist danuglipron among patients with type2 diabetes (T2D).

It was established in the trial that danuglipron reduced glycated hemoglobin and fasting plasma glucose at all doses, and body weight at the highest doses, at week 16 compared with placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK